<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11369">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579345</url>
  </required_header>
  <id_info>
    <org_study_id>V58P4E2</org_study_id>
    <secondary_id>2006-003077-27</secondary_id>
    <nct_id>NCT00579345</nct_id>
  </id_info>
  <brief_title>Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup</brief_title>
  <official_title>A Phase III, Single-Blind, Multi-Center, Extension Study to Evaluate Safety and Tolerability of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adult and Elderly Subjects Who Participated in Study V58P4, With Subset Analyses of Immunogenicity and Evaluation of Concomitant Polysaccharide Pneumococcal Vaccine (Elderly).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study primarily aims to evaluate immunogenicity and safety of influenza vaccines (cell
      culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine
      (egg-derived seasonal trivalent, thiomersal free; eTIV_a)) when administered alone and when
      administered concomitantly with pneumococcal polysaccharide vaccine (PV) in elderly
      subjects. The Study also aimed to evaluate safety and immunogenicity (subset) of annual
      vaccination with either cTIV or eTIV_a in adults and elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Randomized Participants Reporting Local and Systemic Reactions</measure>
    <time_frame>One week postvaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability evaluation of influenza vaccines, within one week of single intramuscular injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Assessment by Geometric Mean Titers (GMT)</measure>
    <time_frame>Three weeks postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-inferiority of the influenza vaccine FLU (cell-culture derived seasonal trivalent influenza vaccine (cTIV); and influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)) when administered alone versus administered concomitantly with pneumococcal vaccine (FLU + PV) is met if lower limit of the 2-sided 95% confidence interval (CI) of postvaccination (Day 22) Geometric Mean Titer ratio (FLU+PV/FLU) is greater than 0.5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Unrandomized Participants Reporting Local and Systemic Reactions</measure>
    <time_frame>One week postvaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability evaluation of influenza vaccines, within one week of single intramuscular injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Randomized Participants Reporting Local and Systemic Reactions.</measure>
    <time_frame>One week postvaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability evaluation, within one week of single intramuscular injection of influenza vaccines (cell-culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) when administered alone or concomitantly with a pneumococcal vaccine (PV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Response as Assessed by Hemagglutination Inhibition Assay</measure>
    <time_frame>Three weeks postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity (Seroconversion or significant increase in antibody titer and HI titer ≥1:40) of cell cultured and egg based trivalent influenza vaccine three weeks after a single injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the Committee for Medicinal Products for Human Use (CHMP) criteria (CPMP/BWP/214/96).
Seroconversion was defined as negative pre-vaccination titer (&lt;10)/postvaccination titer ≥40. Significant increase in antibody titer was defined as at least a fourfold increase from non-negative baseline (≥10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMR Day 22/Day1) After Single Dose of Influenza Vaccine</measure>
    <time_frame>Three weeks postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity (geometric mean titer ratio) of cell cultured and egg based trivalent influenza vaccine three weeks after a single injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the Committee for Medicinal Products for Human Use (CHMP) criteria (CPMP/BWP/214/96).
CHMP Criteria fulfilled if the Geometric Mean titer Ratio (GMR) is &gt;2.5.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1522</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>cTIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cell culture derived seasonal trivalent influenza vaccine (cTIV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eTIV_a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLU (cTIV or eTIV_a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLU (cTIV or eTIV_a) + PV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV); or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell culture derived seasonal trivalent influenza vaccine (cTIV)</intervention_name>
    <description>cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 ml single dose in the deltoid muscle, preferably of the non-dominant arm.</description>
    <arm_group_label>cTIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).</intervention_name>
    <description>egg based trivalent influenza vaccine (eTIV_a) administered as 0.5 ml single dose in the deltoid muscle, preferably of the non-dominant arm.</description>
    <arm_group_label>eTIV_a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cTIV or eTIV_a</intervention_name>
    <description>0.5 ml, Single dose of either cell cultured trivalent influenza vaccine (cTIV)or egg based trivalent influenza vaccine eTIV_a administered.</description>
    <arm_group_label>FLU (cTIV or eTIV_a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cTIV+PV OR eTIV_a+PV</intervention_name>
    <description>0.5 ml, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).</description>
    <arm_group_label>FLU (cTIV or eTIV_a) + PV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participation in the V58P4 study

          -  mentally competent to understand the nature, the scope and the consequences of the
             study

          -  able and willing to give written informed consent prior to study entry

          -  available for all the visits scheduled in the study

        Exclusion Criteria:

          -  receipt of another investigational agent within 90 days prior to, or before
             completion of the safety follow-up period in another study, whichever is longer,
             prior to Visit 7 and unwilling to refuse participation in another clinical study
             through the end of the present study

          -  history of any anaphylaxis, serious vaccine reactions, or allergy to any of the
             vaccine components

          -  any acute respiratory disease or infections requiring systemic antibiotic or
             antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is
             acceptable) or experienced fever (i.e., axillary temperature ≥ 38°C) within the 5
             days prior to Visit 7

          -  pregnant/breast feeding women, or women of childbearing potential who refuse to use a
             reliable contraceptive method during the three weeks after vaccination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>5</name>
      <address>
        <city>Krakow</city>
        <zip>25-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1</name>
      <address>
        <city>Krakow</city>
        <zip>30-969</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4</name>
      <address>
        <city>Krakow</city>
        <zip>31-832</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 24, 2012</lastchanged_date>
  <firstreceived_date>December 19, 2007</firstreceived_date>
  <firstreceived_results_date>September 5, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted during the period of October 2007 to June 2008 at five sites in Poland.</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial. The data entered is for overall study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>cTIV (Adults)</title>
          <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in the parent (V58P4 [NCT00492063]) and the extension 1 (V58P4E1 [NCT00306527]) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine [cTIV] were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="P2">
          <title>eTIV_a (Adults)</title>
          <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) studies with influenza virus vaccine[egg-derived seasonal trivalent, thiomersal free; eTIV_a] were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="P3">
          <title>cTIV (Elderly)</title>
          <description>Revaccination unrandomized group (elderly subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine [cTIV] were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="P4">
          <title>eTIV_a (Elderly)</title>
          <description>Revaccination unrandomized group (elderly subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) study with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a] were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="P5">
          <title>cTIV (Elderly; FLU Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were revaccinated with cell-culture derived seasonal trivalent influenza vaccine [cTIV]; in the deltoid muscle, preferably of the non-dominant arm) irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study.</description>
        </group>
        <group group_id="P6">
          <title>cTIV+PV (Elderly; Concomitant Vaccination )</title>
          <description>Revaccination randomized group (elderly subjects were concomitantly revaccinated with cell-culture derived seasonal trivalent influenza vaccine [cTIV; in the deltoid muscle, preferably of the non-dominant arm] and pneumococcal vaccine [PV; in opposite arm] irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
        <group group_id="P7">
          <title>eTIV_a (Elderly; FLU Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were revaccinated with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a] in the deltoid muscle, preferably of the non-dominant arm irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
        <group group_id="P8">
          <title>eTIV_a +PV (Elderly; Concomitant Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were concomitantly revaccinated with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a in the deltoid muscle, preferably of the non-dominant arm] and pneumococcal vaccine [PV; in opposite arm] irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="549"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="391"/>
                <participants group_id="P4" count="144"/>
                <participants group_id="P5" count="90"/>
                <participants group_id="P6" count="78"/>
                <participants group_id="P7" count="57"/>
                <participants group_id="P8" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="544"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="389"/>
                <participants group_id="P4" count="143"/>
                <participants group_id="P5" count="90"/>
                <participants group_id="P6" count="78"/>
                <participants group_id="P7" count="57"/>
                <participants group_id="P8" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>cTIV (Adults)</title>
          <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in the parent (V58P4 [NCT00492063]) and the extension 1 (V58P4E1 [NCT00306527]) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine [cTIV] were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="B2">
          <title>eTIV_a (Adults)</title>
          <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) studies with influenza virus vaccine[egg-derived seasonal trivalent, thiomersal free; eTIV_a] were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="B3">
          <title>cTIV (Elderly)</title>
          <description>Revaccination unrandomized group (elderly subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine [cTIV] were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="B4">
          <title>eTIV_a (Elderly)</title>
          <description>Revaccination unrandomized group (elderly subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) study with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a] were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="B5">
          <title>cTIV (Elderly; FLU Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were revaccinated with cell-culture derived seasonal trivalent influenza vaccine [cTIV]; in the deltoid muscle, preferably of the non-dominant arm) irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study.</description>
        </group>
        <group group_id="B6">
          <title>cTIV+PV (Elderly; Concomitant Vaccination )</title>
          <description>Revaccination randomized group (elderly subjects were concomitantly revaccinated with cell-culture derived seasonal trivalent influenza vaccine [cTIV; in the deltoid muscle, preferably of the non-dominant arm] and pneumococcal vaccine [PV; in opposite arm] irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
        <group group_id="B7">
          <title>eTIV_a (Elderly; FLU Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were revaccinated with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a] in the deltoid muscle, preferably of the non-dominant arm irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
        <group group_id="B8">
          <title>eTIV_a +PV (Elderly; Concomitant Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were concomitantly revaccinated with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a in the deltoid muscle, preferably of the non-dominant arm] and pneumococcal vaccine [PV; in opposite arm] irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="549"/>
                <measurement group_id="B2" value="169"/>
                <measurement group_id="B3" value="391"/>
                <measurement group_id="B4" value="144"/>
                <measurement group_id="B5" value="90"/>
                <measurement group_id="B6" value="78"/>
                <measurement group_id="B7" value="57"/>
                <measurement group_id="B8" value="44"/>
                <measurement group_id="B9" value="1522"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Unrandomized adults</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44" spread="12.3"/>
                <measurement group_id="B2" value="43.3" spread="12.4"/>
                <measurement group_id="B3" value="NA">This category does not belong to unrandomized adults</measurement>
                <measurement group_id="B4" value="NA">This category does not belong to unrandomized adults</measurement>
                <measurement group_id="B5" value="NA">This category does not belong to unrandomized adults</measurement>
                <measurement group_id="B6" value="NA">This category does not belong to unrandomized adults</measurement>
                <measurement group_id="B7" value="NA">This category does not belong to unrandomized adults</measurement>
                <measurement group_id="B8" value="NA">This category does not belong to unrandomized adults</measurement>
                <measurement group_id="B9" value="43.9" spread="12.3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unrandomized elderly</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="NA">This category does not belong to unrandomized elderly</measurement>
                <measurement group_id="B2" value="NA">This category does not belong to unrandomized elderly</measurement>
                <measurement group_id="B3" value="71.5" spread="5.5"/>
                <measurement group_id="B4" value="72.4" spread="5.7"/>
                <measurement group_id="B5" value="NA">This category does not belong to unrandomized elderly</measurement>
                <measurement group_id="B6" value="NA">This category does not belong to unrandomized elderly</measurement>
                <measurement group_id="B7" value="NA">This category does not belong to unrandomized elderly</measurement>
                <measurement group_id="B8" value="NA">This category does not belong to unrandomized elderly</measurement>
                <measurement group_id="B9" value="71.7" spread="5.6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Randomized elderly</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="NA">This category does not belong to randomized elderly</measurement>
                <measurement group_id="B2" value="NA">This category does not belong to randomized elderly</measurement>
                <measurement group_id="B3" value="NA">This category does not belong to randomized elderly</measurement>
                <measurement group_id="B4" value="NA">This category does not belong to randomized elderly</measurement>
                <measurement group_id="B5" value="71.6" spread="5.9"/>
                <measurement group_id="B6" value="71.5" spread="5.5"/>
                <measurement group_id="B7" value="71.2" spread="4.9"/>
                <measurement group_id="B8" value="71.1" spread="5.2"/>
                <measurement group_id="B9" value="71.4" spread="5.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="318"/>
                <measurement group_id="B2" value="102"/>
                <measurement group_id="B3" value="232"/>
                <measurement group_id="B4" value="90"/>
                <measurement group_id="B5" value="46"/>
                <measurement group_id="B6" value="40"/>
                <measurement group_id="B7" value="38"/>
                <measurement group_id="B8" value="25"/>
                <measurement group_id="B9" value="891"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="231"/>
                <measurement group_id="B2" value="67"/>
                <measurement group_id="B3" value="159"/>
                <measurement group_id="B4" value="54"/>
                <measurement group_id="B5" value="44"/>
                <measurement group_id="B6" value="38"/>
                <measurement group_id="B7" value="19"/>
                <measurement group_id="B8" value="19"/>
                <measurement group_id="B9" value="631"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unrandomized Participants Reporting Local and Systemic Reactions</title>
        <description>Safety and tolerability evaluation of influenza vaccines, within one week of single intramuscular injection.</description>
        <time_frame>One week postvaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in the parent (V58P4) and the extension 1 (V58P4E1) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine (cTIV) were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a (Adults)</title>
            <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in parent (V58P4) and Extension 1 (V58P4E1) studies with influenza virus vaccine(egg-derived seasonal trivalent, thiomersal free; eTIV_a) were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
          </group>
          <group group_id="O3">
            <title>cTIV (Elderly)</title>
            <description>Revaccination unrandomized group (elderly subjects who were pre-vaccinated in parent (V58P4) and Extension 1 (V58P4E1) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine (cTIV) were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a (Elderly)</title>
            <description>Revaccination unrandomized group (elderly subjects who were pre-vaccinated in parent (V58P4) and Extension 1 (V58P4E1) study with influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="168"/>
                  <measurement group_id="O3" value="391"/>
                  <measurement group_id="O4" value="144"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Unrandomized Participants Reporting Local and Systemic Reactions</title>
            <description>Safety and tolerability evaluation of influenza vaccines, within one week of single intramuscular injection.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Local Reactions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="185"/>
                  <measurement group_id="O2" value="60"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="158"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="64"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Systemic Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                  <measurement group_id="O2" value="28"/>
                  <measurement group_id="O3" value="57"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (≥ 38°C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Analgesic and Antipyretics used</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Randomized Participants Reporting Local and Systemic Reactions.</title>
        <description>Safety and tolerability evaluation, within one week of single intramuscular injection of influenza vaccines (cell-culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) when administered alone or concomitantly with a pneumococcal vaccine (PV).</description>
        <time_frame>One week postvaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>FLU (cTIV or eTIV_a) + PV</title>
            <description>Elderly subjects randomized and received influenza vaccine (cell-culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) concomitantly with pneumococcal vaccine (PV).</description>
          </group>
          <group group_id="O2">
            <title>FLU (cTIV or eTIV_a)</title>
            <description>Elderly subjects randomized and received only Influenza vaccine (cell-culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).</description>
          </group>
          <group group_id="O3">
            <title>cTIV (Elderly; FLU Vaccination)</title>
            <description>Revaccination randomized group (elderly subjects were revaccinated with cell-culture derived seasonal trivalent influenza vaccine (cTIV; in the deltoid muscle, preferably of the non-dominant arm) irrespective of influenza vaccination received in parent (V58P4) study or extension 1 (V58P4E1) study.</description>
          </group>
          <group group_id="O4">
            <title>cTIV+PV (Elderly; Concomitant Vaccination )</title>
            <description>Revaccination randomized group (elderly subjects were concomitantly revaccinated with cell-culture derived seasonal trivalent influenza vaccine (cTIV; in the deltoid muscle, preferably of the non-dominant arm) and pneumococcal vaccine (PV; in opposite arm) irrespective of influenza vaccination received in parent (V58P4) study or extension 1 (V58P4E1) study).</description>
          </group>
          <group group_id="O5">
            <title>eTIV_a (Elderly; FLU Vaccination)</title>
            <description>Revaccination randomized group (elderly subjects were revaccinated with influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) in the deltoid muscle, preferably of the non-dominant arm irrespective of influenza vaccination received in parent (V58P4) study or extension 1 (V58P4E1) study).</description>
          </group>
          <group group_id="O6">
            <title>eTIV_a+PV (Elderly; Concomitant Vaccination)</title>
            <description>Revaccination randomized group (elderly subjects were concomitantly revaccinated with influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) in the deltoid muscle, preferably of the non-dominant arm) and pneumococcal vaccine (PV; in opposite arm) irrespective of influenza vaccination received in parent (V58P4) study or extension 1 (V58P4E1) study).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="135"/>
                  <measurement group_id="O3" value="83"/>
                  <measurement group_id="O4" value="84"/>
                  <measurement group_id="O5" value="52"/>
                  <measurement group_id="O6" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Randomized Participants Reporting Local and Systemic Reactions.</title>
            <description>Safety and tolerability evaluation, within one week of single intramuscular injection of influenza vaccines (cell-culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) when administered alone or concomitantly with a pneumococcal vaccine (PV).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Local Reactions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="32"/>
                  <measurement group_id="O5" value="20"/>
                  <measurement group_id="O6" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="5"/>
                  <measurement group_id="O6" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="12"/>
                  <measurement group_id="O5" value="11"/>
                  <measurement group_id="O6" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="5"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="4"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="23"/>
                  <measurement group_id="O5" value="8"/>
                  <measurement group_id="O6" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Systemic Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="22"/>
                  <measurement group_id="O5" value="9"/>
                  <measurement group_id="O6" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="3"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="3"/>
                  <measurement group_id="O6" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="3"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="3"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="5"/>
                  <measurement group_id="O6" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="3"/>
                  <measurement group_id="O6" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="10"/>
                  <measurement group_id="O5" value="1"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (≥ 38°C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Analgesic and Antipyretics used</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="3"/>
                  <measurement group_id="O6" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Randomized Participants Reporting Local and Systemic Reactions</title>
        <description>Safety and tolerability evaluation of influenza vaccines, within one week of single intramuscular injection.</description>
        <time_frame>One week postvaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV Total (Elderly)</title>
            <description>Revaccination randomized group total (elderly subjects who received only (cell-culture derived seasonal trivalent influenza vaccine (cTIV) in the deltoid muscle, preferably of the non-dominant arm; or received concomitant pneumococcal vaccine (PV; in opposite arm).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a Total (Elderly)</title>
            <description>Revaccination randomized group total (elderly subjects who received only influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) in the deltoid muscle, preferably of the non-dominant arm; or received concomitant pneumococcal vaccine (PV; in opposite arm).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="167"/>
                  <measurement group_id="O2" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Randomized Participants Reporting Local and Systemic Reactions</title>
            <description>Safety and tolerability evaluation of influenza vaccines, within one week of single intramuscular injection.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Local Reactions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Systemic Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (≥ 38°C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Analgesic and Antipyretics used</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Response as Assessed by Hemagglutination Inhibition Assay</title>
        <description>Immunogenicity (Seroconversion or significant increase in antibody titer and HI titer ≥1:40) of cell cultured and egg based trivalent influenza vaccine three weeks after a single injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the Committee for Medicinal Products for Human Use (CHMP) criteria (CPMP/BWP/214/96).
Seroconversion was defined as negative pre-vaccination titer (&lt;10)/postvaccination titer ≥40. Significant increase in antibody titer was defined as at least a fourfold increase from non-negative baseline (≥10).</description>
        <time_frame>Three weeks postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in the parent (V58P4 [NCT00492063]) and the extension 1 (V58P4E1 [NCT00306527]) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine (cTIV) were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a (Adults)</title>
            <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) studies with influenza virus vaccine(egg-derived seasonal trivalent, thiomersal free; eTIV_a) were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
          </group>
          <group group_id="O3">
            <title>cTIV Total (Elderly)</title>
            <description>Revaccination randomized group total (elderly subjects who received only (cell-culture derived seasonal trivalent influenza vaccine (cTIV) in the deltoid muscle, preferably of the non-dominant arm; or received concomitant pneumococcal vaccine (PV; in opposite arm).</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a Total (Elderly)</title>
            <description>Revaccination randomized group total (elderly subjects who received only influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) in the deltoid muscle, preferably of the non-dominant arm; or received concomitant pneumococcal vaccine (PV; in opposite arm).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="89"/>
                  <measurement group_id="O4" value="62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Antibody Response as Assessed by Hemagglutination Inhibition Assay</title>
            <description>Immunogenicity (Seroconversion or significant increase in antibody titer and HI titer ≥1:40) of cell cultured and egg based trivalent influenza vaccine three weeks after a single injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the Committee for Medicinal Products for Human Use (CHMP) criteria (CPMP/BWP/214/96).
Seroconversion was defined as negative pre-vaccination titer (&lt;10)/postvaccination titer ≥40. Significant increase in antibody titer was defined as at least a fourfold increase from non-negative baseline (≥10).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HI titer ≥1:40 (H1N1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94" lower_limit="94" upper_limit="100"/>
                  <measurement group_id="O2" value="23" lower_limit="85" upper_limit="100"/>
                  <measurement group_id="O3" value="85" lower_limit="89" upper_limit="99"/>
                  <measurement group_id="O4" value="55" lower_limit="78" upper_limit="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>seroconversion (H1N1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57" lower_limit="49" upper_limit="70"/>
                  <measurement group_id="O2" value="13" lower_limit="34" upper_limit="77"/>
                  <measurement group_id="O3" value="62" lower_limit="59" upper_limit="79"/>
                  <measurement group_id="O4" value="41" lower_limit="53" upper_limit="78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (H3N2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92" lower_limit="91" upper_limit="99"/>
                  <measurement group_id="O2" value="22" lower_limit="78" upper_limit="100"/>
                  <measurement group_id="O3" value="86" lower_limit="90" upper_limit="99"/>
                  <measurement group_id="O4" value="59" lower_limit="87" upper_limit="99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>seroconversion (H3N2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40" lower_limit="32" upper_limit="53"/>
                  <measurement group_id="O2" value="8" lower_limit="16" upper_limit="57"/>
                  <measurement group_id="O3" value="32" lower_limit="26" upper_limit="47"/>
                  <measurement group_id="O4" value="25" lower_limit="28" upper_limit="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (B)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57" lower_limit="49" upper_limit="70"/>
                  <measurement group_id="O2" value="16" lower_limit="47" upper_limit="87"/>
                  <measurement group_id="O3" value="56" lower_limit="52" upper_limit="73"/>
                  <measurement group_id="O4" value="33" lower_limit="40" upper_limit="66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>seroconversion (B)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39" lower_limit="31" upper_limit="52"/>
                  <measurement group_id="O2" value="8" lower_limit="16" upper_limit="57"/>
                  <measurement group_id="O3" value="26" lower_limit="17" upper_limit="36"/>
                  <measurement group_id="O4" value="18" lower_limit="18" upper_limit="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio (GMR Day 22/Day1) After Single Dose of Influenza Vaccine</title>
        <description>Immunogenicity (geometric mean titer ratio) of cell cultured and egg based trivalent influenza vaccine three weeks after a single injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the Committee for Medicinal Products for Human Use (CHMP) criteria (CPMP/BWP/214/96).
CHMP Criteria fulfilled if the Geometric Mean titer Ratio (GMR) is &gt;2.5.</description>
        <time_frame>Three weeks postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in the parent (V58P4 [NCT00492063]) and the extension 1 (V58P4E1 [NCT00306527]) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine (cTIV) were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_a (Adults)</title>
            <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) studies with influenza virus vaccine(egg-derived seasonal trivalent, thiomersal free; eTIV_a) were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
          </group>
          <group group_id="O3">
            <title>cTIV Total (Elderly)</title>
            <description>Revaccination randomized group total (elderly subjects who received only (cell-culture derived seasonal trivalent influenza vaccine (cTIV) in the deltoid muscle, preferably of the non-dominant arm; or received concomitant pneumococcal vaccine (PV; in opposite arm).</description>
          </group>
          <group group_id="O4">
            <title>eTIV_a Total (Elderly)</title>
            <description>Revaccination randomized group total (elderly subjects who received only influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) in the deltoid muscle, preferably of the non-dominant arm; or received concomitant pneumococcal vaccine (PV; in opposite arm).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="89"/>
                  <measurement group_id="O4" value="62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Ratio (GMR Day 22/Day1) After Single Dose of Influenza Vaccine</title>
            <description>Immunogenicity (geometric mean titer ratio) of cell cultured and egg based trivalent influenza vaccine three weeks after a single injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the Committee for Medicinal Products for Human Use (CHMP) criteria (CPMP/BWP/214/96).
CHMP Criteria fulfilled if the Geometric Mean titer Ratio (GMR) is &gt;2.5.</description>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMR (H1N1; A/Solomon Islands/3/2006)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.6" lower_limit="4.27" upper_limit="7.34"/>
                  <measurement group_id="O2" value="4.38" lower_limit="2.52" upper_limit="7.6"/>
                  <measurement group_id="O3" value="7.75" lower_limit="5.93" upper_limit="10"/>
                  <measurement group_id="O4" value="5.92" lower_limit="4.29" upper_limit="8.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMR (H3N2; A/Wisconsin/67/2005)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.63" lower_limit="2.83" upper_limit="4.64"/>
                  <measurement group_id="O2" value="2.33" lower_limit="1.41" upper_limit="3.85"/>
                  <measurement group_id="O3" value="2.65" lower_limit="2.22" upper_limit="3.16"/>
                  <measurement group_id="O4" value="2.89" lower_limit="2.34" upper_limit="3.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMR (B; B/Malaysia/2506/2004)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.48" lower_limit="4.43" upper_limit="5.84"/>
                  <measurement group_id="O2" value="2.33" lower_limit="1.35" upper_limit="3.99"/>
                  <measurement group_id="O3" value="2.51" lower_limit="1.96" upper_limit="3.21"/>
                  <measurement group_id="O4" value="2.97" lower_limit="2.21" upper_limit="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Assessment by Geometric Mean Titers (GMT)</title>
        <description>Non-inferiority of the influenza vaccine FLU (cell-culture derived seasonal trivalent influenza vaccine (cTIV); and influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)) when administered alone versus administered concomitantly with pneumococcal vaccine (FLU + PV) is met if lower limit of the 2-sided 95% confidence interval (CI) of postvaccination (Day 22) Geometric Mean Titer ratio (FLU+PV/FLU) is greater than 0.5.</description>
        <time_frame>Three weeks postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>FLU (cTIV or eTIV_a) + PV</title>
            <description>Elderly subjects randomized and received influenza vaccine (cell-culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) concomitantly with pneumococcal vaccine (PV).</description>
          </group>
          <group group_id="O2">
            <title>FLU (cTIV or eTIV_a)</title>
            <description>Elderly subjects randomized and received only Influenza vaccine (cell-culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Immunogenicity Assessment by Geometric Mean Titers (GMT)</title>
            <description>Non-inferiority of the influenza vaccine FLU (cell-culture derived seasonal trivalent influenza vaccine (cTIV); and influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)) when administered alone versus administered concomitantly with pneumococcal vaccine (FLU + PV) is met if lower limit of the 2-sided 95% confidence interval (CI) of postvaccination (Day 22) Geometric Mean Titer ratio (FLU+PV/FLU) is greater than 0.5.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT Day 22 (H1N1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="138" lower_limit="104" upper_limit="182"/>
                  <measurement group_id="O2" value="198" lower_limit="151" upper_limit="259"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Day 22 (H3N2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="184" lower_limit="141" upper_limit="240"/>
                  <measurement group_id="O2" value="228" lower_limit="176" upper_limit="296"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Day 22 (B)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36" lower_limit="27" upper_limit="47"/>
                  <measurement group_id="O2" value="52" lower_limit="40" upper_limit="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority null hypothesis stated that the FLU+PV vaccine group is non-inferior to the FLU alone group if the lower limit of the 95% CI of the ratio of GMTs between vaccines (FLU+PV/FLU alone) on day 22 is greater than 0.5 for all three vaccine strains.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority is met if lower limit of the 2-sided 95% confidence interval (CI) of the ratio of the postvaccination (Day 22) Geometric Mean Titers (FLU+PV/FLU vaccine alone) is greater than 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>A/H1N1(Day22)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority null hypothesis stated that the FLU+PV vaccine group is non-inferior to the FLU alone group if the lower limit of the 95% CI of the ratio of GMTs between vaccines (FLU+PV/FLU alone) on day 22 is greater than 0.5 for all three vaccine strains.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority is met if lower limit of the 2-sided 95% confidence interval (CI) of the ratio of the postvaccination (Day 22) Geometric Mean Titers (FLU+PV/FLU vaccine alone) is greater than 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>A/H3N2 (Day 22)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority null hypothesis stated that the FLU+PV vaccine group is non-inferior to the FLU alone group if the lower limit of the 95% CI of the ratio of GMTs between vaccines (FLU+PV/FLU alone) on day 22 is greater than 0.5 for all three vaccine strains.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority is met if lower limit of the 2-sided 95% confidence interval (CI) of the ratio of the postvaccination (Day 22) Geometric Mean Titers (FLU+PV/FLU vaccine alone) is greater than 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>B (Day 22)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire study period (six months)</time_frame>
      <desc>Data provided in the &quot;Other Adverse Events (&gt;5%)&quot; includes solicited local and systemic reactions collected within the first 7 days following vaccination along with unsolicited Adverse Events (AEs) collected within first three weeks after the vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>cTIV (Adults)</title>
          <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in the parent (V58P4 [NCT00492063]) and the extension 1 (V58P4E1 [NCT00306527]) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine [cTIV] were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="E2">
          <title>eTIV_a (Adults)</title>
          <description>Revaccination unrandomized group (adult subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) studies with influenza virus vaccine[egg-derived seasonal trivalent, thiomersal free; eTIV_a] were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="E3">
          <title>cTIV (Elderly)</title>
          <description>Revaccination unrandomized group (elderly subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) studies and received at least one dose of cell-culture derived seasonal trivalent influenza vaccine [cTIV] were allocated to receive cTIV or subjects who participated only in the parent study and received or were planned to receive cTIV in study E1 were allocated to receive cTIV in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="E4">
          <title>eTIV_a (Elderly)</title>
          <description>Revaccination unrandomized group (elderly subjects who were pre-vaccinated in parent (V58P4 [NCT00492063]) and Extension 1 (V58P4E1 [NCT00306527]) study with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a] were allocated to receive eTIV_a in the deltoid muscle, preferably of the non-dominant arm).</description>
        </group>
        <group group_id="E5">
          <title>cTIV (Elderly; FLU Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were revaccinated with cell-culture derived seasonal trivalent influenza vaccine [cTIV]; in the deltoid muscle, preferably of the non-dominant arm) irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study.</description>
        </group>
        <group group_id="E6">
          <title>cTIV+PV (Elderly; Concomitant Vaccination )</title>
          <description>Revaccination randomized group (elderly subjects were concomitantly revaccinated with cell-culture derived seasonal trivalent influenza vaccine [cTIV; in the deltoid muscle, preferably of the non-dominant arm] and pneumococcal vaccine [PV; in opposite arm] irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
        <group group_id="E7">
          <title>eTIV_a (Elderly; FLU Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were revaccinated with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a] in the deltoid muscle, preferably of the non-dominant arm irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
        <group group_id="E8">
          <title>eTIV_a +PV (Elderly; Concomitant Vaccination)</title>
          <description>Revaccination randomized group (elderly subjects were concomitantly revaccinated with influenza virus vaccine [egg-derived seasonal trivalent, thiomersal free; eTIV_a in the deltoid muscle, preferably of the non-dominant arm] and pneumococcal vaccine [PV; in opposite arm] irrespective of influenza vaccination received in parent (V58P4 [NCT00492063]) study or extension 1 (V58P4E1 [NCT00306527]) study).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infraction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myocardial infraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Iridocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vitreous prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hepato-biliary disorders cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Diagnostic procedure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neurilemmoma Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rectal Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Motor neurone disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervix adenomatous polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="213" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
